As discussed at the Alzheimer’s Association International Conference in Philadelphia, nearly two dozen mutation carriers who took gantenerumab for eight years had half the risk of developing symptoms as did untreated controls.
First Success Stories From Alzheimer’s Secondary Prevention Trial (Links to an external site)
